Business
AstraZeneca : Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio
AstraZeneca : Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney
About this update from Astrazeneca Plc
11.8% weight loss achieved at 36 weeks in adults with obesity or overweight in VISTA Phase IIb trialHbA1c lowered by 1.9% at 26 weeks in adults with type 2 diabetes in SOLSTICE Phase IIb trialExtensive Phase III programme for elecoglipron planned including outcome trials Positive results from the VISTA and SOLSTICE Phase IIb trials of elecoglipron, an oral small molecule GLP-1 receptor agonist (GLP-1 RA), unlock the next chapter in AstraZeneca's ambition to develop therapies that improve cardiometabolic and kidney health and reduce weight-related complications. These results, presented today at the 2026 Scientific Sessions of the American Diabetes Association (ADA) and simultaneously published in The Lancet, mark an important step in building AstraZeneca's differentiated weight management portfolio of monotherapies and combinations, supported by the Company's broad CVRM pipeline and global commercial expertise. AstraZeneca is advancing elecoglipron into an extensive Phase III programme in obesity and type 2 diabetes, including cardiovascular and kidney outcome trials. In VISTA (n=310), adults with obesity or overweight and at least one comorbidity receiving elecoglipron (75mg) achieved a clinically meaningful and statistically significant average reduction in body weight of 10.5% at 26 weeks compared to 0.6% with placebo, a dual primary endpoint. Weight loss in participants receiving elecoglipron did not plateau, reaching 11.8% at 36 weeks (75mg) versus 0.3% with placebo. The trial also met the dual primary endpoint of proportion of participants achieving at least 5% weight loss at 26 weeks, with up to 88.8% of participants receiving elecoglipron achieving this threshold. In addition, elecoglipron showed clinically meaningful improvements in several exploratory analyses of cardiometabolic risk factors including lower blood pressure and C-reactive protein levels, a marker of systemic inflammation. In SOLSTICE (n=404), adults with type 2 diabetes receiving elecoglipron (75mg) achieved a clinically meaningful and statistically significant average reduction in HbA1c of 1.9% from baseline at 26 weeks compared to 0.2% with placebo, the trial's primary endpoint. The majority of participants receiving elecoglipron (75mg) achieved guideline recommended glycaemic targets by 26 weeks, with 90% reaching an HbA1c of less than 7% and 85% reaching an HbA1c of 6.5% or lo...